| The role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer K Perdrizet, NB Leighl Current treatment options in oncology 20 (3), 21, 2019 | 36 | 2019 |
| Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel–cyclophosphamide chemotherapy for breast cancer: a systematic review R Fernandes, S Mazzarello, C Stober, L Vandermeer, S Dudani, ... Breast cancer research and treatment 161, 1-10, 2017 | 29 | 2017 |
| Point of care molecular testing: community-based rapid next-generation sequencing to support cancer care BS Sheffield, A Beharry, J Diep, K Perdrizet, MAJ Iafolla, W Raskin, ... Current Oncology 29 (3), 1326-1334, 2022 | 26 | 2022 |
| Primary febrile neutropenia prophylaxis for patients who receive FEC-D chemotherapy for breast cancer: a systematic review R Fernandes, S Mazzarello, C Stober, MFK Ibrahim, S Dudani, K Perdrizet, ... Journal of Global Oncology 4, 1-8, 2017 | 16 | 2017 |
| Upfront next generation sequencing in non-small cell lung cancer S Kuang, AS Fung, KA Perdrizet, K Chen, JJN Li, LW Le, M Cabanero, ... Current Oncology 29 (7), 4428-4437, 2022 | 12 | 2022 |
| Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system K Perdrizet, TL Stockley, JH Law, A Smith, T Zhang, R Fernandes, ... Cancer Treatment and Research Communications 31, 100534, 2022 | 9 | 2022 |
| Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian … K Perdrizet, T Stockley, JH Law, M Shabir, T Zhang, LW Le, A Lau, ... Journal of Clinical Oncology 37 (15_suppl), 2620-2620, 2019 | 7 | 2019 |
| P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience K Perdrizet, T Stockley, J Law, M Shabir, L Le, M Tsao, S Kamel-Reid, ... Journal of Thoracic Oncology 13 (10), S717, 2018 | 4 | 2018 |
| Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada K Perdrizet, R Sutradhar, Q Li, N Liu, CC Earle, NB Leighl Journal of Thoracic Disease 13 (9), 5419, 2021 | 3 | 2021 |
| Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience. SCM Lau, K Perdrizet, D Giffoni de Mello Morais Mata, AS Fung, G Liu, ... Journal of Clinical Oncology 39 (15_suppl), e21123-e21123, 2021 | 3 | 2021 |
| Programmed cell death protein 1 inhibitors and MET targeted therapies in NSCLC with MET exon 14 skipping mutations: Efficacy and toxicity as sequential therapies SCM Lau, K Perdrizet, AS Fung, DGMM Mata, J Weiss, N Holzapfel, G Liu, ... JTO Clinical and Research Reports 4 (10), 100562, 2023 | 2 | 2023 |
| A guide to implementing immune checkpoint inhibitors within a cancer program: experience from a large Canadian community centre PK Cheema, MAJ Iafolla, M Nematollahi, FR Berco, D Kaushik, ... Current Oncology 29 (2), 869-880, 2022 | 2 | 2022 |
| Impact of an immuno-oncology (IO) education/monitoring program on patient’s self-efficacy and adverse event reporting from immune checkpoint inhibitors (ICIs). PK Cheema, M Nematollahi, FR Berco, J Papadakos, D Kaushik, ... Journal of Clinical Oncology 38 (15_suppl), 2032-2032, 2020 | 2 | 2020 |
| Rapid point of care NGS in colorectal cancer. W Raskin, P Cheema, K Perdrizet, M Iafolla, S Dudani, B Sheffield Journal of Clinical Oncology 40 (4_suppl), 172-172, 2022 | 1 | 2022 |
| The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer K Perdrizet, PK Cheema Current Oncology 28 (6), 5408-5421, 2021 | 1 | 2021 |
| Impact of fertility preservation by ovarian stimulation on breast cancer outcomes. Y Wang, S Lee, P Camateros, KA Perdrizet, D Yokom, E Warner, ... Journal of Clinical Oncology 35 (15_suppl), e21588-e21588, 2017 | 1 | 2017 |
| Impact on turnaround times (TAT) among non-squamous non-small cell lung cancer (NSCLC) patients across three time periods with varying biomarker testing techniques. Z Fan, R Tudor, LW Le, JH Law, AS Fung, S Kuang, N Meti, K Perdrizet, ... Journal of Clinical Oncology 41 (16_suppl), 9085-9085, 2023 | | 2023 |
| 1151P Evolution of biomarker testing among non-squamous/non-small cell lung cancer (NSCLC) patients (Pts) and impact on turnaround times (TAT) Z Fan, R Tudor, L Le, J Law, S Kuang, N Meti, A Fung, K Perdrizet, ... Annals of Oncology 33, S1076, 2022 | | 2022 |
| Rapid access to biomarker data in a community setting: Integration of next-generation sequencing into routine pathologic workflow. K Perdrizet, PK Cheema, A Beharry, J Diep, M Iafolla, W Raskin, S Dudani, ... Journal of Clinical Oncology 40 (16_suppl), 3143-3143, 2022 | | 2022 |
| Mitigating the risk of COVID-19 in a large community oncology clinic and its impact on the patient experience. R Kang, R Dhir, M Iafolla, W Raskin, S Dudani, J Husain, M Balcewicz, ... Journal of Clinical Oncology 40 (16_suppl), e18631-e18631, 2022 | | 2022 |
